Skip to content

Sunshine Biopharma Inc.: 10-Q filed 2023-08-10

What Sunshine Biopharma Inc. reported in its quarterly report filed 2023-08-10 (fiscal Q2 2023): 44 published measures, 126 facts as tagged in accession 0001683168-23-005518.

This filing

Form
10-Q (quarterly report)
Filed
2023-08-10
Fiscal period
fiscal Q2 2023
Accession
0001683168-23-005518 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Sunshine Biopharma Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2023-06-3028,410,022USD
At 2022-12-3129,243,848USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2023-06-305,300,229USD
At 2022-12-317,616,278USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2023-06-3023,109,793USD
At 2023-03-3119,429,478USD
At 2022-12-3121,627,570USD
At 2022-06-3041,886,280USD
At 2022-03-3113,314,108USD
At 2021-12-31211,662USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2023-06-3019,729,491USD
At 2022-12-3121,826,437USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-902,108USD91
2023-01-01 to 2023-06-30-2,604,538USD181
2022-04-01 to 2022-06-30-538,872USD91
2022-01-01 to 2022-06-30-1,775,106USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-5,628,146USD181
2022-01-01 to 2022-06-30-1,878,010USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2023-01-01 to 2023-06-30454,980USD181
2022-01-01 to 2022-06-300USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2023-04-01 to 2023-06-305,560,865USD91
2023-01-01 to 2023-06-3010,454,918USD181
2022-04-01 to 2022-06-30150,307USD91
2022-01-01 to 2022-06-30272,952USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2023-01-01 to 2023-06-303,519,672USD181
2022-01-01 to 2022-06-3041,561,363USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2023-01-01 to 2023-06-30-405,779USD181
2022-01-01 to 2022-06-300USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2023-06-30-62,004,152USD
At 2022-12-31-59,399,614USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2023-04-01 to 2023-06-3025,350,263shares91
2023-01-01 to 2023-06-3023,827,205shares181
2022-04-01 to 2022-06-3015,849,518shares91
2022-01-01 to 2022-06-309,691,625shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2023-04-01 to 2023-06-3025,350,263shares91
2023-01-01 to 2023-06-3023,827,205shares181
2022-04-01 to 2022-06-3015,849,518shares91
2022-01-01 to 2022-06-309,691,625shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-0.02USD/shares91
2023-01-01 to 2023-06-30-0.09USD/shares181
2022-04-01 to 2022-06-30-0.03USD/shares91
2022-01-01 to 2022-06-30-0.18USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2023-04-01 to 2023-06-3087,677USD91
2023-01-01 to 2023-06-30133,947USD181
2022-04-01 to 2022-06-300USD91
2022-01-01 to 2022-06-300USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2023-06-30366,684USD
At 2022-12-31394,249USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-989,623USD91
2023-01-01 to 2023-06-30-2,818,604USD181
2022-04-01 to 2022-06-30-695,796USD91
2022-01-01 to 2022-06-30-1,919,160USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2023-06-3026,098,709USD
At 2022-12-3127,312,334USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2023-04-01 to 2023-06-3027,596USD91
2023-01-01 to 2023-06-3068,671USD181
2022-04-01 to 2022-06-300USD91
2022-01-01 to 2022-06-3012,864USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2023-06-304,660,347USD
At 2022-12-316,931,014USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2023-06-301,759,789USD
At 2022-12-312,802,797USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2023-06-301,233,570USD
At 2023-03-31948,240USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2023-06-302,011,308USD
At 2022-12-311,912,153USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2023-06-304,250,887USD
At 2022-12-313,289,945USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2023-04-01 to 2023-06-301,952,747USD91
2023-01-01 to 2023-06-303,780,869USD181
2022-04-01 to 2022-06-3075,624USD91
2022-01-01 to 2022-06-30138,424USD181

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2023-04-01 to 2023-06-303,608,118USD91
2023-01-01 to 2023-06-306,674,049USD181
2022-04-01 to 2022-06-3074,683USD91
2022-01-01 to 2022-06-30134,528USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2023-04-01 to 2023-06-30368,565USD91
2023-01-01 to 2023-06-30801,490USD181
2022-04-01 to 2022-06-3045,943USD91
2022-01-01 to 2022-06-30407,595USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2023-06-3025,746,302shares
At 2022-12-3122,585,632shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2023-06-3019,729,491USD
At 2022-12-3121,826,437USD
At 2022-06-3041,727,775USD
At 2021-12-312,045,167USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2023-06-3084,422,143USD
At 2022-12-3180,841,752USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2023-06-30665,056USD
At 2022-12-31161,847USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2023-06-30711,059USD
At 2022-12-31760,409USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2023-06-301,233,570USD
At 2022-12-31776,856USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-814,431USD91
2023-01-01 to 2023-06-30-2,470,591USD181
2022-04-01 to 2022-06-30-538,872USD91
2022-01-01 to 2022-06-30-1,775,106USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2023-04-01 to 2023-06-30-410,059USD91
2023-01-01 to 2023-06-30-2,101,329USD181
2022-04-01 to 2022-06-30-551,517USD91
2022-01-01 to 2022-06-30-1,786,744USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2023-04-01 to 2023-06-302,942,370USD91
2023-01-01 to 2023-06-306,599,473USD181
2022-04-01 to 2022-06-30771,420USD91
2022-01-01 to 2022-06-302,057,584USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2023-04-01 to 2023-06-3034,877USD91
2023-01-01 to 2023-06-3069,587USD181
2022-04-01 to 2022-06-302,287USD91
2022-01-01 to 2022-06-305,397USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2023-04-01 to 2023-06-308,096USD91
2023-01-01 to 2023-03-317,853USD90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2023-04-01 to 2023-06-30175,192USD91
2023-01-01 to 2023-06-30348,013USD181
2022-04-01 to 2022-06-30156,924USD91
2022-01-01 to 2022-06-30144,054USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2023-01-01 to 2023-06-300USD181
2022-01-01 to 2022-06-3061,151USD181

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2023-01-01 to 2023-06-300USD181
2022-01-01 to 2022-06-300USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2023-01-01 to 2023-06-304,089,208USD181
2022-01-01 to 2022-06-3043,560,363USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-06-3055,160USD181
2022-01-01 to 2022-06-30-7,774USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2023-01-01 to 2023-06-30885,243USD181
2022-01-01 to 2022-06-3099,721USD181

Inspect the source

Entity
Sunshine Biopharma Inc. / CIK 0001402328
Captured
2026-09-20T08:00:47.083Z
SEC response SHA-256
089eb69bd01c2bc993f5073ccdb651eba31ddb7f7ea640d657095dcd4ddd9932

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001402328.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))